07:35 AM EDT, 05/09/2024 (MT Newswires) -- Merck ( MRK ) said Thursday that a late-stage trial assessing its cancer drug Keytruda plus chemotherapy as adjuvant treatment, with or without radiotherapy, did not meet its primary endpoint of disease-free survival, or DFS, for the treatment of high-risk endometrial cancer post-surgery.

Merck ( MRK ) said the trial's other primary endpoint of overall survival was not formally tested since superiority was not reached for DFS.

The company said the study did not identify any new safety signals associated with Keytruda.

Price: 129.00, Change: -0.55, Percent Change: -0.42